Sjelden sett et bedre eksempel på at de store og tålmodige kjøper, de små og utålmodige selger enn i dag.
Synes tvert i mot det ser ut som det er store poster som presser ned prisen. Salgstilbudet lå på 57, så la noen(DNM) ut 30000 aksjer til 55.75 salg limit.
Har valgt å se på det som en fin kjøpsmulighet
Definitivt en kjøpsmulighet, prisen faller flere prosent på meget lav omsetning:
http://www.netfonds.no/quotes/paperbroker.php?paper=NANO.OSE
Solgte min lille post i går på 56. Kjøpte tilbake i dag på 53.50.
Liker ikke å være ute av Nano fant jeg ut… 
Teknisk sett så aner jeg robust støtte rundt 50 både basert på omsetningen i September samt SMA50, en annen ting er jo at det vaker godt med triggere fremover. Så jeg sitter godt i ro.
Edit:
Om ikke kursen faller ytterligere nå, da bruker jeg denne månedens sparing på Nano fremfor mer Kitron.
Hvis man skal kjøpe bør man legge seg ,025-0,50 øre litt høyere enn støtten Men det vet du nok. Jeg så intradag at RSI var for lav og begynte å vende opp + det lå solide kjøp lenger nede (53-52). Kombinert med laber salgsvilje på disse nivåene anser jeg kjøpet mitt som trygt.
Sparte noen kroner på denne traden, men det var skummelt.
Så lenge du jobber intradag etter børsen åpner er jo risikoen ikke enorm, jeg synes nano alltid legger ut børsmeldinger sju-åtte tiden om morgenen.
Men å sitte ute over natta vil jeg si er litt ballsy.
Ja, jeg sov ikke spesielt godt for å si det slik. Ikke vært borti en aksje som kan gå så mye på så kort tid som Nano. Men skulle gjerne hatt mer cash for denne bunnen tror jeg ikke vi ser særlig lenge mtp. resultat fra arm 4 som kommer ila. Q4.
03.11.2016 14:22:51: Nordic Nanovector: Updated results from Phase 1/2 trial of Betalutin® in non-Hodgkin lymphoma to be presented at ASH annual meeting in December
Oslo, Norway, 3 November 2016
Nordic Nanovector ASA (OSE: NANO) announces that updated results and analysis
from its ongoing Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan
-lilotomab) in subjects with relapsed/refractory non-Hodgkin lymphoma (NHL) will
be presented in a poster at the 58th Annual American Society of Hematology (ASH)
meeting (3-6 December 2016 in San Diego, CA, USA).
The Lymrit 37-01 study is an ongoing Phase 1/2 open label, single injection
ascending dose study investigating three dose levels of Betalutin® and different
pre-dosing regimens in patients with relapsed NHL with the aim of identifying an
optimal dose regimen to take into the pivotal Phase 2.
The poster will provide an update of safety and efficacy results (including
duration of response) in the Lymrit 37-01 trial to those previously presented in
April at the American Association of Cancer Research (AACR) annual meeting (21
patients) and to those noted in the abstract published by ASH today (abstract
1780), which includes data as of 8 August 2016 (date of submission of the
abstract to ASH), based on 24 evaluable NHL patients from 36 patients enrolled
at the time. See details on abstract 1780 below.
The poster will include the first available safety and efficacy results from
patients enrolled into Arms 3 and 4 of the trial who received two different pre
-dosing regimens prior to Betalutin® injection.
The ASH annual meeting is the premier event for scientific exchange in the field
of hematology, attracting more than 20,000 attendees from all over the world.
Typically, more than 5,000 scientific abstracts are submitted each year, and
more than 3,000 abstracts are accepted for oral and poster presentations through
an extensive peer review process.
Poster details
Abstract 1780
Abstract title: 177lu-Satetraxetan-Lilotomab in the Treatment of Patients with
Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data
from Four Different Pre-Dosing Regimens
Authors: Kolstad, A et al.
Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell
Lymphoma-Clinical Studies: Poster I
Date/Time: Saturday, 3 December 2016, 5:30 PM - 7:30 PM (Pacific Std Time)
Location: San Diego Convention Center, Hall GH
Link to abstract: https://ash.confex.com/ash/2016/webprogram/Paper97356.html
For further information, please contact:
IR enquiries:
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601
Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com
Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk
About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and oncology.
The Company’s lead clinical-stage product opportunity is Betalutin®, the first
in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve
upon and complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and orphan drug
opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously
referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177).
The preliminary data has shown promising efficacy and safety profile in an
ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The
Company is aiming at developing Betalutin® for the treatment of major types of
NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate
in the commercialisation of Betalutin® in core markets, while exploring
potential distribution agreements in selected geographies. The Company is
committed to developing its ARC pipeline to treat multiple selected cancer
indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to the disclose requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
1 Like
Lol. Som jeg sa, meldingene kommer alltid tidlig på morgenen, right? 
1 Like
Dæven… hvor heldig kan man være? Ut i går på 56, inn i dag på 53,50 og melding. Bam! Money in the bank!
1 Like
Fortjener litt stang inn av og til og.
1 Like
03.11.2016 14:38:39: Nordic Nanovector: Results from preclinical studies of Betalutin® in combination with rituximab in non-Hodgkin lymphoma model to be presented at ASH
Oslo, Norway, 3 November 2016
Nordic Nanovector ASA (OSE: NANO) announces that a poster describing the
therapeutic effect of combined treatment with Betalutin® (177Lu-satetraxetan
-lilotomab) and rituximab in a preclinical model of non-Hodgkin lymphoma (NHL)
(abstract 4189) will be presented at the 58th Annual American Society of
Hematology (ASH) meeting (3-6 December 2016 in San Diego, CA, USA). These
studies build on previously presented data showing that treatment with
Betalutin® increased binding of rituximab to NHL cells and uptake of rituximab
in NHL tumours. The combination treatment resulted in 90-100 % survival for 150
days after treatment, while each treatment alone gave from 10 to 40 % survival.
The ASH annual meeting is the premier event for scientific exchange in the field
of hematology, attracting more than 20,000 attendees from all over the world.
Typically, more than 5,000 scientific abstracts are submitted each year, and
more than 3,000 abstracts are accepted for oral and poster presentations through
an extensive peer review process.
Poster details
Abstract 4189
Abstract title: Combination of 177lutetium-Satetraxetan-Lilotomab and Rituximab
Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin
Lymphoma
Authors: Repetto-Llamazares, AHV et al.
Session Name: 625. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents:
Poster III
Date/Time: Monday, 5 December 2016, 6:00 PM - 8:00 PM (PST)
Location: San Diego Convention Center, Hall GH
Link to abstract: https://ash.confex.com/ash/2016/webprogram/Paper89561.html
For further information, please contact:
IR enquiries:
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601
Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com
Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk
About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and oncology.
The Company’s lead clinical-stage product opportunity is Betalutin®, the first
in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve
upon and complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and orphan drug
opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously
referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177).
The preliminary data has shown promising efficacy and safety profile in an
ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The
Company is aiming at developing Betalutin® for the treatment of major types of
NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate
in the commercialisation of Betalutin® in core markets, while exploring
potential distribution agreements in selected geographies. The Company is
committed to developing its ARC pipeline to treat multiple selected cancer
indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to the disclose requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
For de som kjøpte når første melding kom så var kursen ned -0,5 kr, nå er den opp 5,25! Grei trade det!
Denne aksjen er en rollercoaster altså.
1 Like
Lest meldingene litt nøyere nå. Det er egentlig ingenting her som tilsier at aksjen skal videre fra 60 i denne omgang isolert sett, men nå har vi bygd enda litt mer støtte i det området vi allerede har snakket om.
Hvis noen har lyst til å selge NANO fra 55 og nedover nå må de for all del gjøre det, men jeg skjønner ikke logikken.
1 Like
Er jo bare info om når det skal komme mer info!
Men det gjorde godt for psyken med litt blått 
1 Like
Gjorde veldig godt med en knallblå dag!! Hegnar har skrevet litt også: http://www.hegnar.no/Nyheter/Boers-finans/2016/11/Meldingen-som-blaaste-liv-i-Nordic-Nanovector
Blir det krangling om aksjene imorgen?
1 Like
Enig i at meldingen er litt svada sånn sett. Jeg kan virkelig ikke se noen ny info her… museforsøkene var kjent, i allefall har de før dokumentert effekt på mus (det må de før de får lov å gjøre forsøk på mennesker). Tviler på denne vil sende kursen mot 70 kr, men konferansen 3. desember og resultater der kan fort sende oss opp 10-20% hvis de er positive!
1 Like
04.11.2016 07:00:23: Safety Review Committee for Nordic Nanovector’s Lymrit 37-01 trial recommends dose escalation to 20 MBq/kg with Betalutin®
Oslo, Norway, 4 November 2016
Nordic Nanovector ASA (OSE: NANO) announces that the independent Safety Review
Committee (SRC) for the ongoing Lymrit 37-01 clinical trial of Betalutin® in
relapsed/refractory NHL, has recommended escalating the dose of Betalutin® in
Arm 4 from 15 MBq/kg to 20 MBq/kg following pre-dosing with 100 mg/m2 lilotomab.
Recruitment of 3 patients into Arm 4 to receive this new higher dosing regimen
is now underway. The SRC also concluded that Arm 3 should be discontinued.
The decision follows a review by the SRC of the available safety and dosimetry
data from the first cohorts of 3 patients each enrolled in Arms 3 and 4 to
determine which arm should continue, if dose escalation is warranted and to what
extent. Patients in Arm 3 were pre-dosed with standard rituximab immunotherapy
prior to receiving 15 MBq/kg Betalutin® ; patients in Arm 4 received 100 mg/m2
lilotomab prior to 15 MBq/kg Betalutin®.
The SRC recommendation for advancing Arm 4 was based on safety data
demonstrating that pre-dosing with 100 mg/m2 lilotomab prior to Betalutin®
reduces bone marrow toxicity as a result of lower absorbed radiation dose to
this tissue. In addition, available dosimetry data from Arm 4 showed that higher
pre-dosing does not prevent therapeutically relevant amounts of Betalutin® being
taken up into the tumours.
Update on dose escalation in Arm 1/Phase 2
The SRC has also agreed that the company can change the treatment regimen used
in Arm 1/Phase 2 to match that used in Arm 4. The dose of Betalutin® specified
in Phase 2 will be increased from 15 MBq/kg to 20 MBq/kg pending review of the
safety data from the first 3 patients treated in Arm 4 with 20 MBq/kg.
Escalation to the new higher dosing regimen in Arm 1/Phase 2 will also require
the approval of a protocol amendment by the European regulators. The planned
amendment will allow for additional patients to be enrolled into Arm 1/Phase 2,
which is expected to contribute to building a more robust safety database,
particularly with data from patients receiving the new higher dosing regimen.
Luigi Costa, Nordic Nanovector CEO, commented: “This is an important milestone
in the development of Betalutin® in FL. We are delighted with outcome of the SRC
review that provides us with the opportunity to test a higher dose of
Betalutin®. We believe that the new dosing regimen will deliver an even higher
efficacy than that so far observed and favourable safety, based on the evidence
to date. We are confident that we will meet our goal of having a clear view on
the optimum dosing regimen to use in the pivotal PARADIGME trial by the end of
the first quarter 2017 as planned.”
About Lymrit 37-01
The LYMRIT 37-01 study is an ongoing Phase 1/2 open label, single injection
ascending dose study investigating in three dose levels of Betalutin® and
different pre-dosing regimens in patients with relapsed NHL with the aim of
identifying an optimal dose regimen to take into a pivotal Phase 2 PARADIGME
trial.
Updated results from the Lymrit 37-01 trial including those in Arms 3 and 4,
will be presented at the 58th Annual American Society of Hematology (ASH)
meeting on 3 December 2016.
For further information, please contact:
IR enquiries:
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601
Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com
Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk
About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and oncology.
The Company’s lead clinical-stage product opportunity is Betalutin®, the first
in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve
upon and complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and orphan drug
opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously
referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177).
The preliminary data has shown promising efficacy and safety profile in an
ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The
Company is aiming at developing Betalutin® for the treatment of major types of
NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate
in the commercialisation of Betalutin® in core markets, while exploring
potential distribution agreements in selected geographies. The Company is
committed to developing its ARC pipeline to treat multiple selected cancer
indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to the disclose requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
1 Like